A5071741514- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Cancer, Lipids, and Metabolism
- Urological Disorders and Treatments
- Urologic and reproductive health conditions
- Urinary and Genital Oncology Studies
- Advanced Radiotherapy Techniques
- Cancer, Hypoxia, and Metabolism
- Renal cell carcinoma treatment
- Hormonal and reproductive studies
- Urinary Bladder and Prostate Research
- Cancer Treatment and Pharmacology
- BRCA gene mutations in cancer
- Cytokine Signaling Pathways and Interactions
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- PARP inhibition in cancer therapy
- Ureteral procedures and complications
- Health Systems, Economic Evaluations, Quality of Life
- Molecular Biology Techniques and Applications
- Pediatric Urology and Nephrology Studies
- Epigenetics and DNA Methylation
- Renal and related cancers
Thomas Jefferson University
2016-2025
Sidney Kimmel Cancer Center
2016-2025
Thomas Jefferson University Hospital
2012-2024
Philadelphia University
2010-2020
Nashville Oncology Associates
2020
Augusta University
2020
CARE Canada
2019
Mayo Clinic
2017
University of Pennsylvania
1997-2017
Fox Chase Cancer Center
2017
We conducted a study to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased for disease.
Abstract Small non‐coding microRNAs (miRNAs) contribute to cancer development and progression, are differentially expressed in normal tissues cancers. However, the specific role of miRNAs metastatic process is still unknown. To seek a miRNA expression signature characterizing phenotype solid tumours, we performed microarray analysis on 43 paired primary tumours (ten colon, ten bladder, 13 breast, lung cancers) one their related lymph nodes. We identified comprising 15 overexpressed 17...
PARP-1 is an abundant nuclear enzyme that modifies substrates by poly(ADP-ribose)-ylation. has well-described functions in DNA damage repair and also as a context-specific regulator of transcription factors. With multiple models, data show elicits protumorigenic effects androgen receptor (AR)-positive prostate cancer cells, both the presence absence genotoxic insult. Mechanistically, recruited to sites AR function, therein promoting occupancy function. It was further confirmed genetically...
Significance MicroRNAs (miRNAs) are small ∼22-nt RNAs that important regulators of posttranscriptional gene expression. Since their initial discovery, they have been shown to be involved in many cellular processes, and misexpression is associated with disease etiology. Currently, nearly 2,800 human miRNAs annotated public repositories. A key question miRNA research how harbored by the genome. To answer this question, we examined 1,323 short RNA sequence samples identified 3,707 novel miRNAs,...
Retinoblastoma (RB; encoded by RB1) is a tumor suppressor that frequently disrupted in tumorigenesis and acts multiple cell types to suppress cycle progression. The role of RB progression, however, poorly defined. Here, we have identified critical for protecting against progression through regulation targets distinct from control. In analyses human prostate cancer samples, loss was infrequently observed primary disease predominantly associated with transition the incurable,...
We compared hexaminolevulinate (Hexvix) fluorescence cystoscopy with white light for detecting carcinoma in situ.In this multicenter study 298 patients known or suspected bladder cancer underwent instillation 50 ml 8 mM 1 hour. Cystoscopy was then performed, first using standard and cystoscopy. Lesions suspicious areas identified under the 2 illumination conditions were mapped biopsied histological examination. In addition, directed biopsy obtained from an area appearing to be normal.Of 196...
We compared hexaminolevulinate fluorescence cystoscopy with white light for detecting Ta and T1 papillary lesions in patients bladder cancer.A total of 311 known or suspected cancer underwent instillation 50 ml 8 mM HAL 1 hour. The was inspected using cystoscopy, followed by blue (fluorescence) cystoscopy. Papillary were mapped resected histological examination.Noninvasive pTa tumors found 108 196 evaluable (55.1%). In 31 (29%) at least more tumor detected than (p<0.05). Six these had no...
Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary assessment. Critical needs include optimized multigene strategies that incorporate evolving genetic data, consistency in GT indications alternate evaluation models address the rising demand for services. A multidisciplinary consensus conference included experts, stakeholders, national organization leaders was convened response to current practice challenges develop implementation...
The optimal timing of postoperative radiotherapy (RT) after radical prostatectomy (RP) is unclear. We hypothesized that a genomic classifier (GC) would provide prognostic and predictive insight into the development clinical metastases in men receiving post-RP RT inform decision making.
Open AccessJournal of UrologyAdult Urology5 May 2024Efficacy Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non–muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial Vikram M. Narayan, Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, Neal D. Shore, Leonard G. Gomella, Ashish Kamat, Trinity J. Bivalacqua, Jeffrey S. Montgomery, Seth P. Lerner, Joseph E. Busby, Michael Poch, Paul L. Crispen, Gary Steinberg, Anne K. Schuckman, Tracy Downs,...
No AccessJournal of UrologyAdult Urology: Oncology: Prostate/Testis/Penis/Urethra1 Oct 2004CHEMOPREVENTION OF PROSTATE CANCER IN MEN AT HIGH RISK: RATIONALE AND DESIGN THE REDUCTION BY DUTASTERIDE EVENTS (REDUCE) TRIAL GERALD ANDRIOLE, DAVID BOSTWICK, OTIS BRAWLEY, LEONARD GOMELLA, MICHAEL MARBERGER, DONALD TINDALL, SHARON BREED, MATT SOMERVILLE, ROGER RITTMASTER, and REDUCE STUDY GROUP ANDRIOLEGERALD ANDRIOLE Financial interest and/or other relationship with Abbott Laboratories, Antigenics,...
PURPOSE To evaluate the antitumor activity of 96-hour paclitaxel and daily oral estramustine phosphate (EMP) in patients with metastatic hormone-refractory prostate cancer (HRPC). PATIENTS AND METHODS Thirty-four adenocarcinoma that progressed after one or more hormonal therapies a trial antiandrogen withdrawal were enrolled onto this phase II trial. Patients received 120 mg/m2 by intravenous (i.v.) infusion on days 1 through 4 each 21-day cycle, together EMP 600 mg/m2/d, continuously....
PurposeTo test the hypothesis that a genomic classifier (GC) would predict biochemical failure (BF) and distant metastasis (DM) in men receiving radiation therapy (RT) after radical prostatectomy (RP).Methods MaterialsAmong patients who underwent post-RP RT, 139 were identified for pT3 or positive margin, did not receive neoadjuvant hormones had paraffin-embedded specimens. Ribonucleic acid was extracted from highest Gleason grade focus applied to high-density-oligonucleotide microarray....
We have recently discovered that the insulin-like growth factor receptor I (IGF-IR) is up-regulated in human invasive bladder cancer and promotes migration invasion of transformed urothelial cells. The proteoglycan decorin, a key component tumor stroma, can positively regulate IGF-IR system normal However, there are no available data on role decorin modulating activity cells or models. Here we show expression inversely correlated with low high grade cancers (n = 20 each). Decorin bound...